|
Main
|
|
Note: This record shows only the 20 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register. |
|
Register:
|
ClinicalTrials.gov |
|
Last refreshed on:
|
17 October 2012 |
|
Main ID: |
NCT00497666 |
|
Date of registration:
|
06/07/2007 |
|
Primary sponsor: |
|
|
Public title:
|
Association Between Rosiglitazone Use and Clinical Course of Diabetic Nephropathy: Population-Based Study
|
|
Scientific title:
|
Retrospective Study Evaluating the Association Between Rosiglitazone Use and Clinical Course of Diabetic Nephropathy: Population-Based Study |
|
Date of first enrolment:
|
August 2007 |
|
Target sample size:
|
|
|
Recruitment status: |
Not yet recruiting |
|
URL:
|
http://clinicaltrials.gov/show/NCT00497666 |
|
Study type:
|
Observational |
|
Study design:
|
Observational Model: Case Control, Time Perspective: Cross-Sectional, Time Perspective: Retrospective
|
|
|
Countries of recruitment
|
|
Israel
| | | | | | | |
|
Contacts
|
|
Name:
|
Leonid S Feldman |
|
Address:
|
|
|
Telephone:
|
+972-8-9779383 |
|
Email:
|
leonidf@asaf.health.gov.il |
|
Affiliation:
|
|
|
|
Name:
|
Leonid S Feldman |
|
Address:
|
|
|
Telephone:
|
+972-8-9779383 |
|
Email:
|
leonidf@asaf.health.gov.il |
|
Affiliation:
|
|
|
|
Name:
|
Leonid S Feldman |
|
Address:
|
|
|
Telephone:
|
|
|
Email:
|
|
|
Affiliation:
|
Assaf-Harofeh Medical Center |
|
|
Name:
|
Leonid S Feldman |
|
Address:
|
|
|
Telephone:
|
|
|
Email:
|
|
|
Affiliation:
|
Nephrology Division, Assaf Harofeh Medical Center, Zerifin, |
| | |
|
Key inclusion & exclusion criteria
|
Inclusion Criteria:
1. Diagnosis of Diabetes Mellitus Type II
2. Treatment With Oral hypoglycemics
3. Availability of Baseline and follow up clinical data
Exclusion Criteria:
1. Insulin Therapy at baseline
2. Malignancy
Age minimum:
18 Years
Age maximum:
90 Years
Gender:
Both
|
|
Health Condition(s) or Problem(s) studied
|
|
Diabetes
|
|
Diabetic Nephropathy
|
|
Renal Protection
|
|
Intervention(s)
|
|
Drug: Rosiglitasone (retrospective observation)
|
|
Secondary ID(s)
|
|
346147Rosi
|
|
Source(s) of Monetary Support
|
|
Please refer to primary and secondary sponsors
|
|